N
NatureCell Co Ltd
KOSDAQ:007390
NatureCell Co Ltd
KOSDAQ:007390
Price:
17 100
KRW
-6.56%
Market Cap:
₩1.1T
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
NatureCell Co Ltd
KOSDAQ:007390
|
KR |
|
Dagi Giyim Sanayi ve Ticaret AS
IST:DAGI.E
|
TR |
|
Cognex Corp
NASDAQ:CGNX
|
US |
|
S
|
Shenzhen FRD Science & Technology Co Ltd
SZSE:300602
|
CN |
|
Okura Industrial Co Ltd
TSE:4221
|
JP |
|
O
|
Oeneo SA
LSE:0O33
|
FR |
|
Hiab Oyj
F:C1C1
|
FI |
|
Alliance Entertainment Holding Corp
NASDAQ:AENT
|
US |
|
Bosch Fren Sistemleri Sanayi ve Ticaret AS
IST:BFREN.E
|
TR |
|
SG Fleet Group Ltd
ASX:SGF
|
AU |
|
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS
IST:RTALB.E
|
TR |
|
Iskenderun Demir ve Celik AS
IST:ISDMR.E
|
TR |
Multiples-Based Value
The Multiples-Based Value of one NatureCell Co Ltd stock under the Base Case scenario is hidden KRW. Compared to the current market price of 17 100 KRW, NatureCell Co Ltd is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NatureCell Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
NatureCell Co Ltd Competitors
NatureCell Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
N
|
NatureCell Co Ltd
KOSDAQ:007390
|
1.1T KRW | 49.8 | -384.4 | -816.4 | -337.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.2B USD | 6.1 | 89.2 | 14.8 | 20.5 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.4B USD | 6.2 | -96.2 | 951.3 | -107.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.4B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169.9B USD | 5.8 | 20 | 12.5 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.6 | 17.8 | 13.2 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.6B AUD | 3.2 | 35.3 | 11.6 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
